China Medical System Holdings Ltd
HKEX:867
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
China Medical System Holdings Ltd
Operating Income
China Medical System Holdings Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Medical System Holdings Ltd
HKEX:867
|
Operating Income
¥1.6B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
4%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Operating Income
¥6.6B
|
CAGR 3-Years
37%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Operating Income
¥9B
|
CAGR 3-Years
42%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Operating Income
¥4.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Operating Income
¥7.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
35%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Operating Income
¥3.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
203%
|
CAGR 10-Years
N/A
|
|
China Medical System Holdings Ltd
Glance View
China Medical System Holdings Ltd., a notable player in the Chinese pharmaceutical landscape, has woven a strategy that cleverly integrates proprietary drug development with a robust marketing apparatus. Established in 1995 and headquartered in Shenzhen, the company has developed a knack for identifying pharmaceuticals and medical devices with promising potential. Their business model hinges on acquiring exclusive rights to a carefully curated portfolio of international products, which they then introduce to the burgeoning Chinese market. By leveraging their deep understanding of market dynamics and regulatory environments, they effectively roll out these products, ensuring that they meet local demand and adhere to high compliance standards. The company's revenue engine is powered predominantly by its dynamic sales and marketing network which spans across mainland China. They employ a multifaceted distribution model, partnering with an extensive range of hospitals and healthcare providers to facilitate widespread adoption of their products. But what truly sets China Medical System Holdings apart is its focus on products that are already well advanced within their lifecycle, minimizing the usual risks associated with early-stage pharmaceutical development. This strategic approach not only ensures steady cash flows but also reduces overhead costs associated with R&D, allowing them to reinvest profits into acquiring new products and expanding their market footprint. As such, their business thrives on a cycle of discernment and targeted expansion, positioning them as a formidable entity in the healthcare sector.
See Also
What is China Medical System Holdings Ltd's Operating Income?
Operating Income
1.6B
CNY
Based on the financial report for Dec 31, 2025, China Medical System Holdings Ltd's Operating Income amounts to 1.6B CNY.
What is China Medical System Holdings Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
4%
Over the last year, the Operating Income growth was -6%. The average annual Operating Income growth rates for China Medical System Holdings Ltd have been -24% over the past three years , -10% over the past five years , and 4% over the past ten years .